Evolus Inc. (EOLS)

15.99
NASDAQ : Health Technology
Prev Close 15.69
Day Low/High 15.63 / 16.28
52 Wk Low/High 10.22 / 30.25
Avg Volume 774.20K
Exchange NASDAQ
Shares Outstanding 27.37M
Market Cap 429.48M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of EOLS August 16th Options Trading

First Week Of EOLS August 16th Options Trading

Investors in Evolus Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EOLS options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal

Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal

Allergan shares surged the most in more than 25 years Tuesday after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie .

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Oversold Conditions For Evolus

Oversold Conditions For Evolus

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ALPHAEON Corporation To Pay Off $88 Million Of Outstanding Third-Party Debt

ALPHAEON Corporation To Pay Off $88 Million Of Outstanding Third-Party Debt

NEWPORT BEACH, Calif., May 21, 2019 /PRNewswire/ -- ALPHAEON Corporation ("ALPHAEON"), announced today that it has completed the sale of 4.

Oversold Conditions For Evolus (EOLS)

Oversold Conditions For Evolus (EOLS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Jim Cramer: These 7 True Laggards Have Caught Fire

Jim Cramer: These 7 True Laggards Have Caught Fire

These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.

ALPHAEON Corporation Sells 4 Million Shares In Evolus Inc.

ALPHAEON Corporation Sells 4 Million Shares In Evolus Inc.

NEWPORT BEACH, Calif., May 15, 2019 /PRNewswire/ -- ALPHAEON Corporation announced today that it has agreed to sell approximately 4.

EOLS: Insiders Vs. Shorts

EOLS: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Evolus Inc is one of the most shorted stocks of the Russell 3000, based on 7.09 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

There's No Compelling Reason to Embrace the Bearish Narrative

There's No Compelling Reason to Embrace the Bearish Narrative

The best move here is to stay focused on stock picking but manage positions tightly.

Evolus Stockholders May Be Frowning in the Short Run

Evolus Stockholders May Be Frowning in the Short Run

Shares of the Botox competitor could correct/consolidate after a recent surge.

Evolus Reaches Analyst Target Price

Evolus Reaches Analyst Target Price

In recent trading, shares of Evolus Inc have crossed above the average analyst 12-month target price of $28.75, changing hands for $28.91/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Shares of Botox maker Allergan slipped after a billionaire hedge-fund manager challenges the company's management.

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Evolus surges Monday after the U.S. Food and Drug Administration approves the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan's Botox.

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.

Evolus Reaches Analyst Target Price

Evolus Reaches Analyst Target Price

In recent trading, shares of Evolus Inc have crossed above the average analyst 12-month target price of $28.00, changing hands for $29.82/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

DocuSign, DexCom, Skechers USA: 'Mad Money' Lightning Round

DocuSign, DexCom, Skechers USA: 'Mad Money' Lightning Round

Jim Cramer weighs in on DocuSign, DexCom, Skechers USA, Campbell Soup, Evolus, Zscaler, Lockheed Martin and more.

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Jim Cramer says there's the market that's about entertainment and anything that delivers entertainment to you. And then there's everything else.

Evolus Reaches Analyst Target Price

In recent trading, shares of Evolus Inc have crossed above the average analyst 12-month target price of $22.50, changing hands for $23.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

Here's what you need to know now for Thursday, May 17.

Allergan's Meury Talks Market Expansion in Aesthetics

Allergan's Meury Talks Market Expansion in Aesthetics

The chief commercial officer's appearance at a Bank of America healthcare conference came a day after Allergan competitor Evolus said it had received a complete response letter regarding its application for Botox rival DWP-450.

INVESTOR ALERT: Investigation On Behalf Of Evolus Investors Announced By Holzer & Holzer

INVESTOR ALERT: Investigation On Behalf Of Evolus Investors Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS) complied with the federal securities laws.

Evolus Phase III European - Canadian Head-to-Head Trial Of PrabotulinumtoxinA Compared To Botox® Meets Primary Endpoint

Evolus Phase III European - Canadian Head-to-Head Trial Of PrabotulinumtoxinA Compared To Botox® Meets Primary Endpoint

Results presented today at 2018 Aesthetic and Anti-Aging Medicine World Congress (AMWC)

Trimming Allergan

This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.

Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival

Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival

Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

The chief commercial officer of the Dublin drugmaker describes the long-term outlook for the medical aesthetics business as 'exceptional.'